Overall, our data confirm that with receipt of HER2-targeted therapy, HER2+ mIBC has similar outcomes to HER2+ metastatic non-IBC, which is different from what has been reported with other subtypes of IBC, commonly associated with worse outcomes compared to non-IBC16,18,19,28. The gene discussed is ERBB2; the disease is inflammatory breast carcinoma.